News InterCure Ltd.

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Delayed TEL AVIV STOCK EXCHANGE 06:58:44 2026-10-20 EDT			5-day change	1st Jan Change
1,444.00 ^ILa	+1.12%		-5.93%	-10.75%

09-08	InterCure Regains Nasdaq Compliance	MT
08-24	InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI

All News

Mentions Relevance

09-08	InterCure Regains Nasdaq Compliance	MT
09-08	InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
08-24	InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
08-24	Intercure Ltd. Finalizes Settlement for War-Related Indirect Damages with the Israeli Tax Authorities and Compensation Fund the Subsequent War	CI
08-24	InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages	AQ
08-19	InterCure Ltd. Announces 1-for-5 Reverse Share Split	AQ
06-22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
06-22	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds	AQ
06-15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
06-15	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
06-14	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
06-14	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
04-30	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ
04-30	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	InterCure Receives Noncompliance Notice From Nasdaq	MT
03-03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
03-03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
02-19	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
02-19	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ
12-18	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
11-03	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
11-03	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI
11-03	InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation	AQ
25-10-08	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-08	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow	RE